Effect of Sylimarin versus placebo on the reduction of liver complication of Teriflunomide in patients with multiple sclerosis
Phase 3
Recruiting
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT20120215009014N467
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Age 18 to 70 years
Multiple sclerosis
Exclusion Criteria
Pregnancy or breastfeeding
Alcohol consumption
Active viral hepatitis or chronic liver disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver and biliary function tests (including AST, ALT, ALP, bilirubin and GGT). Timepoint: Before the intervention and one and two months after the intervention. Method of measurement: By laboratory test.
- Secondary Outcome Measures
Name Time Method